ERBB2 and neoplasm: In contrast, tumor size (HR 1.02, CI 95% 1.0–1.05, p = 0.036) and subtype (HER2-positive vs luminal A, HR 4.45, CI 95% 1.51–13.1, p = 0.007) were associated with increased IBTR risk.